RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and invasion and increases chemosensitivity to cisplatin in human osteosarcoma U2-OS cells in vitro

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1291-1297

  Si, Haipeng ^a   Peng, Changliang ^a   Li, Jingjing ^b   Wang, Xiqian ^a   Zhai, Lianwen ^a   Li, Xiaofeng ^a   Li, Jianmin ^c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Chemosensitivity; ERK1 2; Osteosarcoma; SiRNA

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

ADOLESCENT; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHILD; CISPLATIN; DOWN-REGULATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84863388880     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1303     Document Type: Article

References (44)

1. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
2. Akiyama T, Dass CR and Choong PF: Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 7: 3461-3469, 2008.
3. Inamdar GS, Madhunapantula SV and Robertson GP: Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 80: 624-637, 2010.
4. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006. (Pubitemid 44301348)
5. McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
6. Eisenmann KM, van Brocklin MW, Staffend NA, Kitchen SM and Koo HM: Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 63: 8330-8337, 2003. (Pubitemid 37549486)
7. Satyamoorthy K, Li G, Gerrero MR, et al: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759, 2003. (Pubitemid 36231971)
8. Chen L, Shi Y, Jiang CY, Wei LX, Wang YL and Dai GH: Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg Oncol 37: 513-520, 2011.
9. Barry OP, Mullan B, Sheehan D, et al: Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J Biol Chem 276: 15537-15546, 2001.
10. Sivaraman VS, Wang H, Nuovo GJ and Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483, 1997. (Pubitemid 27163797)
11. Oka H, Chatani Y, Hoshino R, et al: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55: 4182-4187, 1995.
12. Gregorj C, Ricciardi MR, Petrucci MT, et al: ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 109: 5473-5476, 2007. (Pubitemid 46890571)
13. Sridhar SS, Hedley D and Siu LL: Raf kinase as a target for anti-cancer therapeutics. Mol Cancer Ther 4: 677-685, 2005. (Pubitemid 40601850)
14. Yang R, Piperdi S and Gorlick R: Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res 14: 6396-6404, 2008.
15. Shimo T, Matsumura S, Ibaragi S, et al: Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells. J Cell Commun Signal 1: 103-111, 2007.
16. Bass BL: Double-stranded RNA as a template for gene silencing. Cell 101: 235-238, 2000.
17. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008. (Pubitemid 351818697)
18. Iwagaki A, Choe N, Li Y, Hemenway DR and Kagan E: Asbestos inhalation induces tyrosine nitration associated with extracellular signal-regulated kinase 1/2 activation in the rat lung. Am J Respir Cell Mol Biol 28: 51-60, 2003. (Pubitemid 36017050)
19. Van Golen KL, Wu ZF, Qiao XT, Bao LW and Merajver SD: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60: 5832-5838, 2000.
20. Lin JC, Chang SY, Hsieh DS, Lee CF and Yu DS: Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol 174: 2022-2026, 2005.
21. Zhang D, LaFortune TA, Krishnamurthy S, et al: Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 15: 6639-6648, 2009.
22. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A and Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106: 1154-1161, 2006.
23. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007. (Pubitemid 46763022)
24. Montagut C and Settleman J: Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134, 2009.
25. Friday BB and Adjei AA: Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14: 342-346, 2008. (Pubitemid 351226098)
26. Gailhouste L, Ezan F, Bessard A, et al: RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo. Int J Cancer 126: 1367-1377, 2010.
27. Zeng P, Wagoner HA, Pescovitz OH and Steinmetz R: RNA interference (RNAi) for extracellular signal-regulated kinase 1 (ERK1) alone is sufficient to suppress cell viability in ovarian cancer cells. Cancer Biol Ther 4: 961-967, 2005. (Pubitemid 41598591)
28. Koul S, Huang M, Chaturvedi L, Meacham RB and Koul HK: p42/p44 mitogen-activated protein kinase signal transduction pathway regulates interleukin-6 expression in PC3 cells, a line of hormone-refractory prostate cancer cells. Ann NY Acad Sci 1030: 253-257, 2004. (Pubitemid 40378920)
29. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006. (Pubitemid 46094197)
30. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA and Giaccone G: Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 118: 209-214, 2006. (Pubitemid 41681601)
31. Lapteva N, Yang AG, Sanders DE, Strube RW and Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 12: 84-89, 2005. (Pubitemid 39665246)
32. Susa M, Iyer AK, Ryu K, et al: Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 5: e10764, 2010.
33. Pignochino Y, Grignani G, Cavalloni G, et al: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 8: 118, 2009.
34. Do SI, Jung WW, Kim HS and Park YK: The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int J Oncol 34: 797-803, 2009.
35. Gysin S, Lee SH, Dean NM and McMahon M: Pharmacologic inhibition of RAF - >MEK - >ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res 65: 4870-4880, 2005. (Pubitemid 40740826)
36. Sutter AP, Maaser K, Gerst B, Krahn A, Zeitz M and Scherubl H: Enhancement of peripheral benzodiazepine receptor ligand-induced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase. Biochem Pharmacol 67: 1701-1710, 2004. (Pubitemid 38479848)
37. Shukla A, Hillegass JM, Macpherson MB, et al: ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer 129: 1075-1086, 2011.
38. Chen H, Zhu G, Li Y, et al: Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res 69: 9228-9235, 2009.
39. + CML stem/progenitor cells. Leukemia 25: 1159-1167, 2011.
40. Trisciuoglio D, Iervolino A, Zupi G and Del Bufalo D: Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 16: 4153-4162, 2005. (Pubitemid 41262885)
41. Zamble DB and Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20: 435-439, 1995.
42. Mandic A, Viktorsson K, Heiden T, Hansson J and Shoshan MC: The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res 11: 11-19, 2001. (Pubitemid 32158181)
43. Lu Y and Cederbaum A: The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin. Free Radic Biol Med 43: 1061-1075, 2007. (Pubitemid 47302654)
44. Wang J, Zhou JY and Wu GS: ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 67: 11933-11941, 2007.